Curing Cancer Network Newsletter

December 2023

Abstract A135: Are survival benefits of new drugs in combinations due to modest benefits in most patients or large benefits in few patients?

This abstract was presented at a recent conference held by the American Association of Cancer Research, the National Cancer Institute and the European Organisation for Research and Treatment of Cancer. These conferences provide an opportunity for physicians and scientists to present their research.

Bile duct cancer

This is part of our series on cancer from a pathologist's perspective.

Bile duct cancer, also called cholangiocarcinoma, is typically discussed with liver cancer because the bile ducts originate in the liver. However, the cells of bile duct cancer resemble bile ducts and not liver cells, and these cancers behave differently from liver cell cancer (also called hepatocellular carcinoma).

Extrahepatic tumor contains small, dispersed glands and single cells in a haphazard appearance, contributed by Raul S. Gonzalez, M.D.

Cell migration in children and adults

It is important to understand physiologic (normal) cell migration because this process is hijacked by metastatic cancer cells.

White blood cells (purple cells with granules) migrate from blood vessels into infected tissues to destroy bacteria (oval yellow particles with hairlike projections)

Liver Cancer

Liver cancer combined with intrahepatic bile duct cancer is the #6 cause of cancer death in the U.S. (after lung, colon, pancreas, breast and prostate cancer), with 29,380 deaths projected in 2023 (19,000 in men, 10,380 in women).

Liver cancer typically refers to primary liver cancers, i.e. cancers that originate in the liver and resemble liver cells. About 80% of primary liver cancers are liver cell cancer (hepatocellular carcinoma). The rest are usually cancer of the intrahepatic bile ducts (cholangiocarcinoma).

See the rest of the post at https://natpernick.substack.com/p/liver-cancer